26 March 2013
New anti-wrinkle drug challenges Botox
Johnson & Johnson may soon cause frown lines at Allergan Inc, maker of Botox. J&J expects to seek US approval next year for an anti-wrinkle drug that could break Botox's near monopoly, an 85% market share.
What analysts say
about the product
E-cigarettes have become hugely popular in the past decade, but a rash of vaping-linked deaths and illnesses in the US is feeding caution about a product that's already banned in some places.
A new drug works by targeting an immune system antibody called immunoglobulin E, which is responsible for the allergic reaction that causes hives.